Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders
Bristol Myers Squibb announced the presentation of scientific research across cancers and blood disorders at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress that underscores the company’s commitment to delivering transformational therapies for patients. Data from more than 140 company-sponsored studies, investigator-sponsored studies and collaborations evaluating compounds across 28 cancer types and blood disorders will be featured at the two meetings.
Latest Aithority Insights: Komodo Health Platform Accelerates Real-World Evidence For Life Sciences
$BMY announces more than 140 presentations across 28 #cancer types and #blooddisorders, highlighting its efforts in transforming treatment for patients.
“We have made significant progress for patients with cancer and blood disorders by delivering clinically meaningful and differentiated treatment choices across modalities such as CAR T, immunotherapy and erythroid maturation,” said Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb. “Driven by our deep understanding of human biology and leading scientific research, the results being presented at ASCO and EHA will provide greater insight into the potential for improving long-term outcomes, and rationale for moving innovative interventions into earlier lines of treatment. Beyond our data, we are focused on improving care for all patients through our Health Equity Commitments, aimed at increasing diversity in clinical trials, addressing health disparities, and investing in training for racially and ethnically diverse clinical investigators.”
Browse The Complete News About Aithority : Clearlake Capital-Backed Cornerstone Completes Acquisition of EdCast
Key data being presented by Bristol Myers Squibb at ASCO and EHA 2022 include:
- Landmark five-year analysis of CheckMate -227, the longest reported follow-up of a Phase 3 immunotherapy combination study in first-line metastatic non-small cell lung cancer (NSCLC), demonstrate long-term, durable survival outcomes with Opdivo (nivolumab) plus Yervoy (ipilimumab).
- Three-year follow-up data from CheckMate -9LA reinforce the long-term, durable survival outcomes of Opdivo plus Yervoy with two cycles of chemotherapy, in the first-line treatment of patients with metastatic NSCLC, including those with PD-L1 expression <1%.
- Analyses from the CheckMate -816 trial highlight the association between pathological response and improved event-free survival in patients with resectable NSCLC treated with Opdivo plus chemotherapy in the neoadjuvant setting.
- Overall survival and overall response rate data from the RELATIVITY-047 trial evaluating Opdualag (nivolumab and relatlimab-rmbw), the combination of nivolumab, a PD-1 blocking antibody, and relatlimab, a LAG-3 blocking antibody, demonstrate the clinical benefit of the company’s third distinct checkpoint inhibitor in patients with advanced melanoma. These data were first disclosed at the March ASCO Plenary Series.
- With the longest reported follow-up of median overall survival from a Phase 3 advanced melanoma trial, seven and a half-year survival results will be presented on the combination of Opdivo plus Yervoy from CheckMate -067 in patients with advanced melanoma.
- First disclosure of data from the PILOT study of Breyanzi (liso-cel), in patients with relapsed or refractory large B-cell lymphoma after one line of therapy who were not intended for transplant, show substantial durable responses. A patient-reported outcomes analysis from PILOT also showed treatment with Breyanzi improved health-related quality of life measures for patients.
- Correlative analysis of characteristics of patients treated with Abecma (ide-cel) in the KarMMa and KarMMa-2 clinical trials, with CAR T product quality attributes, informs further insights into potentially optimizing patient selection for CAR T manufacturing and improving clinical outcomes.
- Long-term data from pivotal MEDALIST and BELIEVE studies highlight continued benefit of Reblozyl (luspatercept-aamt) for patients with lower-risk myelodysplastic syndromes and transfusion-dependent beta thalassemia (ASCO/EHA).
- Long-term survival results from the pivotal Phase 3 QUAZAR® AML-001 study, highlight the survival benefit of Onureg (azacitidine tablets) following intensive chemotherapy (EHA).
- First dose expansion data for Eisai and Bristol Myers Squibb’s co-developed antibody-drug conjugate MORAb-202, demonstrate anti-tumor activity in platinum-resistant ovarian cancer patients at two dose levels as well as benefits of exploration of body surface area dosing to optimize safety.
- Data from Phase 1 studies of CC-99282, a cereblon E3 ligase modulator (CELMoD®) agent, and CC-95251, an anti-signal regulatory protein-alpha (SIRPα) antibody combined with rituximab, show promising activity in patients with relapsed or refractory non-Hodgkin lymphoma (EHA).
- Health-related quality of life data from the Phase 1/2 MM-001 study of iberdomide plus dexamethasone, underscore the potential of CELMoD® compounds in patients with relapsed or refractory multiple myeloma (EHA).
Read More About Aithority News : New Fintech Startup economyx.AI Uses Machine Learning to Pull Insights From US Economic News
[To share your insights with us, please write to email@example.com]